The economics of medicines optimization: policy developments, remaining challenges and research priorities

TY - JOUR

T1 - The economics of medicines optimization

T2 - policy developments, remaining challenges and research priorities

AU - Faria, Rita

AU - Barbieri, Marco

AU - Light, Kate

AU - Elliott, Rachel A

AU - Sculpher, Mark

N1 - © The Author 2014. Published by Oxford University Press.

PY - 2014

Y1 - 2014

N2 - BACKGROUND: This review scopes the evidence on the effectiveness and cost-effectiveness of interventions to improve suboptimal use of medicines in order to determine the evidence gaps and help inform research priorities.SOURCES OF DATA: Systematic searches of the National Health Service (NHS) Economic Evaluation Database, the Cochrane Database of Systematic Reviews and the Database of Abstracts of Reviews of Effects.AREAS OF AGREEMENT: The majority of the studies evaluated interventions to improve adherence, inappropriate prescribing and prescribing errors.AREAS OF CONTROVERSY: Interventions tend to be specific to a particular stage of the pathway and/or to a particular disease and have mostly been evaluated for their effect on intermediate or process outcomes.GROWING POINTS: Medicines optimization offers an opportunity to improve health outcomes and efficiency of healthcare.AREAS TIMELY FOR DEVELOPING RESEARCH: The available evidence is insufficient to assess the effectiveness and cost-effectiveness of interventions to address suboptimal medicine use in the UK NHS. Decision modelling, evidence synthesis and elicitation have the potential to address the evidence gaps and help prioritize research.

AB - BACKGROUND: This review scopes the evidence on the effectiveness and cost-effectiveness of interventions to improve suboptimal use of medicines in order to determine the evidence gaps and help inform research priorities.SOURCES OF DATA: Systematic searches of the National Health Service (NHS) Economic Evaluation Database, the Cochrane Database of Systematic Reviews and the Database of Abstracts of Reviews of Effects.AREAS OF AGREEMENT: The majority of the studies evaluated interventions to improve adherence, inappropriate prescribing and prescribing errors.AREAS OF CONTROVERSY: Interventions tend to be specific to a particular stage of the pathway and/or to a particular disease and have mostly been evaluated for their effect on intermediate or process outcomes.GROWING POINTS: Medicines optimization offers an opportunity to improve health outcomes and efficiency of healthcare.AREAS TIMELY FOR DEVELOPING RESEARCH: The available evidence is insufficient to assess the effectiveness and cost-effectiveness of interventions to address suboptimal medicine use in the UK NHS. Decision modelling, evidence synthesis and elicitation have the potential to address the evidence gaps and help prioritize research.

U2 - 10.1093/bmb/ldu021

DO - 10.1093/bmb/ldu021

M3 - Article

C2 - 25190760

SN - 0007-1420

VL - 111

SP - 45

EP - 61

JO - British Medical Bulletin

JF - British Medical Bulletin

IS - 1

ER -